- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About MannKind Corp.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.
Stock Analysis
last close
$3.81
1-mo return
-8.9%
3-mo return
3.5%
avg daily vol.
6.47M
52-week high
5.5
52-week low
2.49
market cap.
$980M
forward pe
-
annual div.
-
roe
-
ltg forecast
-
dividend yield
-
annual rev.
$70M
inst own.
46.6%
